Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time
- 1 January 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (S3) , 9-13
- https://doi.org/10.1038/bjc.1998.748
Abstract
Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.Keywords
This publication has 25 references indexed in Scilit:
- Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990European Journal Of Cancer, 1997
- A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinomaCancer, 1991
- EVALUATION OF THE ANTITUMOR-ACTIVITY OF GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE)1990
- MODULATORY ACTIVITY OF 2',2'-DIFLUORODEOXYCYTIDINE ON THE PHOSPHORYLATION AND CYTOTOXICITY OF ARABINOSYL NUCLEOSIDES1990
- A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer, 1990
- COMPARISON OF THE CELLULAR PHARMACOKINETICS AND TOXICITY OF 2',2'-DIFLUORODEOXYCYTIDINE AND 1-BETA-D-ARABINOFURANOSYLCYTOSINE1988
- The memorial pain assessment card. A valid instrument for the evaluation of cancer painCancer, 1987
- Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm)Cancer, 1986
- Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group studyCancer, 1983
- Randomized study of 5-FU and ccnu in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study groupCancer, 1981